

# CENTRAL AND EASTERN EUROPE BIOTECH REPORT

The report you are holding summarizes the biotech landscape across Central and Eastern Europe (CEE) and the Baltics—namely the Czech Republic, Poland, Slovakia, Hungary, and Lithuania, Latvia, and Estonia. Czech biotech builds

on a strong legacy, with pharmaceutical manufacturing in Prague dating back over a century. Today, the Czech Republic stands out for its concentration of talent and scientific output, producing a high density of impactful research relative to its size. More than half of top-quality scientific publications involve collaboration with partners in the United States, Germany, and the United Kingdom. Given the market's scale, Czech biotech companies are globally oriented from the outset, targeting international investors, partners, and customers. These global ambitions translate into rapidly growing ecosystem with wide-ranging impact. Moreover, Prague also serves as a gateway to the wider CEE region, drawing increasing attention from global investors and

biotech community. A clear signal of this momentum is the arrival of BioEquity Europe 2026 to Prague. The conference is held in CEE for the first time, which marks the region's growing importance in biotech and its global aspirations, as well as the government's long-term support for innovative sectors, which is at the heart of the Czech Republic's Economic Strategy.



**Karel Havlíček**  
Minister of Industry and Trade of the Czech Republic

## BIOTECH IN CZECHIA

**427** entities  
companies, research and educational institutions

**4** bn. € / year  
revenue from product and service sales



**1.5** bn. €  
foreign direct investments (2003–2025)

**32.000** employees  
in biotech and life sciences




### STRONG TALENT POOL

**12.000**  
Students

**2.000**  
Biochemistry

**4.100**  
Chemistry

**5.900**  
Biology



Source: Prague.bio, CzechInvest

## BIOTECH IN THE CEE REGION

(Czechia, Slovakia, Poland, Hungary + Baltics)

### HUMAN HEALTHCARE TECHNOLOGIES AND SERVICES

**130%** Growth value-added 2008–2022

**56 bn. €** Turnover

**869.000** Employees = **2,6%** Workforce


**611 mil. €** R&D Investment

Source: Joint Research Centre, European Commission

## BIOTECH STARTUP ENVIRONMENT


**1.584**  
Early stage companies

**220**  
VC + PE investors



Source: Dealroom, data for the CEE

# TIMELINE: BORN IN CEE, SHAPING GLOBAL MEDICINE



## STARTUPS TO WATCH

### Sensible Biotechnologies

— Slovakia

Pioneering the design and manufacturing of mRNA therapeutics using living cells.



### Adalid Sciences

— Czechia

Specializes in the development of lipid nanoparticle (LNP) delivery systems for nucleic acid-based therapeutics, such as mRNA, siRNA, and gene editing tools.



### DIANA Biotechnologies

— Czechia

Czech company providing PCR solutions for diagnostic and life science labs. The name DIANA stands for DNA-linked Inhibitor Antibody Assay—a method that can precisely detect a variety of diseases.



### TurbineAI

— Hungary

Virtualizing biological experiments with AI to accelerate drug discovery and improve clinical translatability. Using its foundational virtual cell model powered by its lab-in-the-loop, Turbine creates virtual copies of experimental assays.



### iQure Pharma

— Poland

Clinical-stage biotech company advancing a novel therapeutic approach for CNS disorders by restoring glutamate homeostasis.



## VCs TO WATCH

Curated list of 10 CEE Biotech VC funds

[i&i Biotech Fund \(Czechia\)](#)

[Tensor Ventures \(Czechia\)](#)

[MetaPlanet \(Estonia\)](#)

[Baltic Sandbox Ventures \(Estonia\)](#)

[Practica Capital \(Lithuania\)](#)

[FlyCap \(Latvia\)](#)

[CB Investment Management \(Slovakia\)](#)

[Inovo.VC \(Poland\)](#)

[YouNickMint \(Poland\)](#)

[Hiventures \(Hungary\)](#)

This report was created by Prague.bio with the support of general partner IOCB Tech and valuable input from SOTIO Biotech and CzechInvest.

PRAGUE BIO

IOCB TEC-H



See the report  
online & download



Contact:  
info@prague.bio